Medical And Smart Business Solutions Will Redefine This Electronics Group’s Future Potential

Catalysts

About Qisda

Qisda is a Taiwan based electronics and solutions group with operations across information technology, medical, smart business solutions, and networking and communications.

What are the underlying business or industry changes driving this perspective?

• Expansion of higher value medical devices and services, including operating room equipment, surgical robots, dialysis and pet dialysis, ultrasound and low intensity focused ultrasound, is broadening Qisda’s addressable market and mix, which can lift group revenue and support gross margin compared with original IT hardware.
• Growth in smart healthcare retail channels, such as BenQ Hearing Aid stores, in store shops within drugstores and cosmetics chains, and overseas hospital smart solutions in markets like Thailand, is increasing recurring service and consumables income, which can improve earnings visibility and support net margins.
• Business Solutions Group focus on computing power, AI enabled smart retail, cybersecurity, industrial PCs and smart automation, supported by M&A and one stop platforms, is tying Qisda into long term digital transformation and automation spending, which can support faster revenue growth and higher OP income margins than legacy products.
• Networking and Communications Group exposure to India and other emerging markets, including FR2 and low band receiver projects for fixed wireless access and future liquid cooling and 1.6 terabit data center switches, positions Qisda to benefit from long running data traffic and connectivity growth, which can scale revenue and help spread fixed costs, supporting OP income.
• Ongoing shift of manufacturing and supply chain to Taiwan, Vietnam, Mexico and other regions to manage tariffs and currency risk, together with hedging policies and tighter inventory control, is aimed at stabilizing gross margin and limiting earnings volatility, which can support more resilient net income over time.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Qisda compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming Qisda's revenue will grow by 4.9% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 0.5% today to 2.6% in 3 years time.
• The bullish analysts expect earnings to reach NT$6.4 billion (and earnings per share of NT$4.13) by about June 2029, up from NT$977.2 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 10.2x on those 2029 earnings, down from 49.3x today. This future PE is lower than the current PE for the TW Tech industry at 23.3x.
• The bullish analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.28%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Qisda’s heavy use of USD for both revenue and inventory costs, combined with NTD as its reporting currency, makes earnings sensitive to currency swings. Management quantified that a 1% NTD appreciation may reduce revenue by 0.7% and gross margin by 0.2 percentage points, which could cap revenue growth and compress net margins if exchange rate volatility persists.
• The group is increasing inventory to support tariff related supply chain shifts to places like Vietnam and Mexico, and also saw higher stock levels from customers pulling in orders ahead of tariff decisions. If demand proves weaker than expected or tariff rules change again, slower inventory turnover and potential write downs could weigh on operating income and earnings.
• High value medical assets and hospital expansions require upfront hiring and equipment spending, while some drugstore locations were affected by flooding in Southern Taiwan. If hospital utilization and retail health traffic do not keep pace with these investments, the combination of higher fixed costs and physical disruption risk could limit improvements in OP income margin and net income.
• The tariff outlook under Section 232 for semiconductor and ICT products, together with signs of weaker purchasing in May, June and July and a softer traditional peak season in IT hardware, creates a risk that third and fourth quarter revenue in IT and networking may not recover as hoped. This would pressure group revenue and make it harder to lift earnings.
• Several networking subsidiaries in NCG, such as Alpha, Hitron and IDT, were in loss in the first half and rely on scaling new areas like India, FR2, fixed wireless access and data center switches. If customer qualifications take longer or competition intensifies, these businesses may continue to drag on group OP income and limit improvement in overall earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Qisda is NT$33.2, which represents up to two standard deviations above the consensus price target of NT$32.6. This valuation is based on what can be assumed as the expectations of Qisda's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be NT$242.3 billion, earnings will come to NT$6.4 billion, and it would be trading on a PE ratio of 10.2x, assuming you use a discount rate of 7.3%.
• Given the current share price of NT$30.5, the analyst price target of NT$33.2 is 8.1% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.